Member Info for substp

And of course, by being on the inside of the Chinese wall, they can provide feedback as a ‘regular market user’. As part of the market abuse rules in the UK, a regular market user is a key test of whether market distortion, or giving a false or misleading impression has taken place. The corporate broker is a good sounding board of whether a planned information strategy is safe or not. http://transparencymatters.blogspot.com/2005/01/dealing-with-city.html

Dealing with the City The closest single advisor relationship maintained by a listed company in the UK is that of his corporate broker. The role of corporate broker is unique to the UK and dates from the historic Stock Exchange requirement that every listed company appoint a “sponsor” to act as intermediary between the company, its shareholders and the Stock Exchange. Today, the role centres upon providing advice, insight and expertise through strong, stable relationships with broking clients and their shareholders alike. This advice has historically centred on market related matters, but corporate broking is now recognised as both the market advocate for their clients and as a trusted adviser on all corporate issues. Linked closely to both the equity capital markets and corporate finance arenas, corporate broking operates on the confidential side of the Chinese wall. The corporate brokers’ role is to give the best possible understanding of the markets and what they are saying and feeling, to help communicate an investment story to the investors, and to help build a high quality investor base. They will also support the issuer in providing appropriate advisory and capital transaction support.

Embargoed until 0700hrs, 9 January 2008 DERMASALVE SCIENCES PLC CHANGE OF BROKER The Directors of DermaSalve Sciences plc (`DermaSalve' or the `Company') announces that it has appointed St. Helen's Capital as its broker with immediate effect. Hanson Westhouse Limited is nominated adviser to the Company. St Helen's Capital was established in 1998 and is authorised and regulated by the Financial Services Authority, a member of the London Stock Exchange and also a Corporate Adviser member of PLUS.

Fantastic news and closer to home ! Isn't that a minimum of almost 24 million £s worth purchases over 5 years ???

Old hat now as they have merged since . Who can spot it ??? Anybody we know ??? A clue - five paragraphs down . http://tinyurl.com/2wvycf And it was : "It is majority owned by its employees and backed by Halifax Bank of Scotland, Invesco and other significant investors." There's that name again .... Another crap company that was looked after by a highly qualified NED . Was Investec his good buddy ???

No buyers then Turncoat ? Maybe it wasn't doing as well as was first let on . A bargain to them alright . I'll find out soon enough .......

What a rip off !!! A third of the price ! And they woudn't tell you who it was either ...... Probably one of the buddies ... "subject to a final adjustment for the net tangible assets transferred to the purchaser" And what assets would they be ????

But you really don't know anything Turncoat or you would have mentioned this about HCEG and MCC . :-))

Please scroll down to "1 background and summary" . If only Aim ... http://www.sec.gov/rules/proposed/33-8407.htm

Strong sell ???? Theres nothing to lose at these prices . LOL

Looks as if Storm is the only smart one here .... :-))

Your post just shows that you really don't have a clue Turncoat . Or do you ??? LOL

Very interesting from the ADVFN VAL BB : http://money.cnn.com/news/deals/mergers/reports/1134161020.html

"HCEG will also receive 400,000 shares and 700,000 warrants in the US-based Cancer Therapeutics, Inc. a biotherapy company that is a leader in activated cell technology for cancer therapy." Nothing but lies ! It's a shell !

We believe our present capital resources are insufficient for ongoing operation. We cannot assure you that we will be able to raise sufficient funds to further develop and market our services. Our lack of funds will materially affect Cancer Therapeutics, and may cause us to cease operations. Consequently, you could incur a loss of your entire investment in Cancer Therapeutics. On July 31, 2007, the Company sold all operating assets to a shareholder of the Company. This transaction resulted in the Company becoming a shell (as defined in Rule 12b-2 of the Exchange Act). Revenues. Cancer Therapeutics generated net revenues of $-0- during the three months ended August 31, 2007, compared to $7,100 in net revenues for the three months ended August 31, 2006. As the Company has entered into shell status, revenues are expected to be at or near zero for the foreseeable future. Personnel Cancer Therapeutics has -0- full-time employees. However, the CEO and other project-based contract personnel are utilized to carry out our business. These project-based contract personnel are temporary engagements used to assist us. What a **** take ! Are they going to use this shell for something else ? http://www.pinksheets.com/edgar/GetFilingPdf?FilingID=5476562 http://www.cancer-therapeutics.com/#

Steven has shed a lot more than todays RNS shows...... http://tinyurl.com/yuaf9c

Pat , you were never very good at looking for things including research . Turncoat , Aye you're probably right but I'm curious as to which way Ebiox and Fertiligent will go .

Why would anyone take on 2 1/2 million shares yesterday ?

Was browsing the new Breatheskincare site and realised that the only thing that you can buy at this time is the Echium Face Cream . All of the rest of it won't be available until January . They are using PayPal and the Postage and Packaging are a reasonable £3.95 (UK ?). http://www.breatheskincare.com/ I really like the site .

DermaSalve Sciences is the holding company for the DermaSalve, SafeCleanse, Healthy & Essential and TC29 brands. http://www.dermasalvesciences.com/group_operations